Nifty Healthcare Index PB	5.3
Nifty Healthcare Index PE	36.7
Nifty Healthcare Index DIV	0.6
Nifty Healthcare Index EPS	385.6

Nifty Healthcare Index News and Updates

Keep track of all breaking news on Nifty Healthcare Index from all sources in a single place.

Sun Pharmaceutical Industries Ltd.

28 Sep 2025, 04:02PM

1586.70

-2.50%

US Tariffs: Only Sun Pharma Exposed To Some Headline Risk, But With Limited Earnings Impact

NDTV Profit

Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US, about 17% of 2024-25 revenue.

Sun Pharmaceutical Industries Ltd. is trading at high day volume of 7.3M.

Sun Pharma hit by US tariff risk, but earnings impact to remain limited

Business Standard | 28 Sep 2025, 12:41PM 1 more

Glenmark Pharmaceuticals Ltd.

28 Sep 2025, 10:48AM

1971.70

-2.91%

Glenmark Pharmaceuticals To Trade Ex-Dividend This Week

NDTV Profit

To be eligible for dividends, investors should take note of the record date, which determines shareholder eligibility.

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Corporate Actions This Week: Glenmark Pharma, Star Housing Finance, Paushak And More

NDTV Profit | 28 Sep 2025, 10:40AM

Apollo Hospitals Enterprise Ltd.

28 Sep 2025, 09:54AM

7510.00

-1.50%

Apollo Hospitals signs agreement with Iraq to manage Internal Security Force Hospital

Business Line

Under the agreement, Apollo Hospitals will provide advanced medical care to Iraq's security forces and their families, further strengthening India's healthcare footprint overseas

Apollo Hospitals Ent.. has an average target of 8259.25 from 4 brokers.

Laurus Labs Ltd.

26 Sep 2025

832.30

-7.15%

Laurus Labs Downplays Impact Of New US Pharma Tariffs On Branded Drugs

NDTV Profit

Lauras Labs derives 40% of its revenue from antiretroviral (ARV) drugs, which remain insulated from US tariffs.

Laurus Labs Ltd.'s price crossed below 50Day SMA today

Sun Pharmaceutical Industries Ltd.

26 Sep 2025

1586.70

-2.50%

Trump Tariffs May Not Hurt Indian Companies, Says Morgan Stanley: THIS Pharma Stock An Exception

NDTV Profit

Morgan Stanley believes the impact could be limited, as far as the Indian market is concerned. However, companies like Sun Pharma could be at risk due to their speciality drug presence in the US.

Sun Pharmaceutical Industries Ltd. is trading below all available SMAs

Trump Slaps 100% Pharma Tariffs: What It Means For Indian Companies

NDTV Profit | 26 Sep 2025

Sun Pharmaceutical Industries Ltd.

26 Sep 2025

1586.70

-2.50%

Sun Pharma hits 52-week low as pharma giants navigate US tariff threat

Business Line

The stock has seen heavy selling pressure with over 52 lakh shares traded, declining 2.96 per cent to 1,579.20, generating turnover of 827.93 crore by 12.50 pm

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Glenmark Pharmaceuticals Ltd.

25 Sep 2025

1971.70

-2.91%

Why Nomura continues to back Glenmark Pharma; Retains 'Buy'; Find out here

Business Standard

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Glenmark Pharma secures global license for Hengrui's cancer drug

Business Line | 24 Sep 2025

Sun Pharmaceutical Industries Ltd.

25 Sep 2025

1586.70

-2.50%

Sun Pharmaceutical: Domestic, innovation push eyed; Nuvama maintains 'Hold'

Business Standard

Sun Pharma aims to strengthen its domestic formulations business through field force expansion and a generic GLP-1 launch in CY26.

Sun Pharmaceutical Industries Ltd. is trading at high day volume of 7.3M.

Lupin Ltd.

24 Sep 2025

1919.80

-2.23%

Lupin gets tentative nod from USFDA for generic HIV treatment drug

Business Standard

Pharma major Lupin Ltd on Wednesday said it has received tentative approval from the US health regulator for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat human immunodeficiency virus (HIV) infection. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets of strength 50 mg/200 mg/25 mg, Lupin said in a regulatory filing. This product would be manufactured at Lupin's Nagpur facility, it added. Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets, 50 mg/200 mg/25 mg are bioequivalent to Biktarvy Tablets, 50 mg/200 mg/25 mg of Gilead Sciences, Inc., and indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg, it added. Citing IQVIA MAT July 2025 data, Lupin said the Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets (Biktarvy) had